Navigation Links
Pulmonary Fibrosis Patients/9/11 Responders Represented at State of the Union Address for Second Year in a Row
Date:1/28/2008

Deadly Lung Disease Claims as Many Lives Each Year as Breast Cancer, Yet Largely Unknown

SAN JOSE, Calif., Jan. 28 /PRNewswire-USNewswire/ -- For the second year in a row, pulmonary fibrosis patients will be represented at the President's State of the Union address. Just a year ago, Caesar Borja, Jr. attended President Bush's State of the Union speech, just hours after his father lost his fight to live as he awaited a lung transplant for pulmonary fibrosis. Tonight, another pulmonary fibrosis patient's family member will attend the State of the Union address.

Joseph Zadroga will attend tonight's address in memory of his son, James Zadroga who died in 2006 to pulmonary fibrosis. Both Zadroga and the senior Borja were members of the New York Police Department during 9/11 and are believed to have been exposed to toxins that could have caused their pulmonary fibrosis, an incurable and deadly lung disease. According to reports, two pathologists agreed that Zadroga's death to pulmonary fibrosis was linked to ground zero contaminants.

"It is a tragedy that every day, hundreds of people lose their lives to this horrific disease," said Mishka Michon, Chief Executive Officer of the Coalition for Pulmonary Fibrosis. "It is our hope that these brave family members can help increase awareness of this deadly disease that receives little funding and little attention from the federal government. We are working hard to find treatments to take this disease from terminal to treatable."

Cases of pulmonary fibrosis are on the rise with more than 150 percent increase in incidence and prevalence of the disease since 2001. There is no FDA approved treatment and no cure for the disease that claims 40,000 lives each year, the same as breast cancer. More than 128,000 people suffer from pulmonary fibrosis and most will die within three years of diagnosis.

For more information, visit http://www.coalitionforpf.org.

About Idiopathic Pulmonary Fibrosis (IPF)

IPF is a lung disorder characterized by a progressive scarring -- known as fibrosis -- and deterioration of the lungs, which slowly robs its victims of their ability to breathe. Approximately 128,000 Americans suffer from IPF, which is the most prevalent of a classification of lung disorders known as interstitial lung diseases (ILD's). There is currently no known cause or cure for IPF, nor is there an FDA-approved treatment. An estimated 48,000 new cases are diagnosed each year. IPF is difficult to diagnose, and an estimated two-thirds of patients die within five years of diagnosis.

About the Coalition for Pulmonary Fibrosis

The Coalition for Pulmonary Fibrosis (CPF) is a 501(c)(3) nonprofit organization, founded in 2001 to accelerate research efforts leading to a cure for idiopathic pulmonary fibrosis (IPF), while educating, supporting, and advocating for the community of patients, families, and medical professionals fighting this disease. The CPF funds promising research into new approaches to treat and cure pulmonary fibrosis; provides patients and families with comprehensive education materials, resources, and hope; serves as a voice for national advocacy of IPF issues; and works to improve awareness of IPF in the medical community as well as the general public. The CPF's nonprofit partners include many of the most respected medical centers and healthcare organizations in the U.S. With more than 15,000 members nationwide, the CPF is the largest nonprofit organization in the U.S. dedicated to advocating for those with pulmonary fibrosis. For more information please visit http://www.coalitionforpf.org or call (888) 222-8541.


'/>"/>
SOURCE Coalition for Pulmonary Fibrosis
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Researchers at Peoria Pulmonary Associates to study airway bypass procedure for emphysema
2. Breakthrough in Pulmonary Drug Delivery will Bring Numerous In-Hospital Treatments to the Home
3. Who is the arch-criminal in the development of hepatopulmonary syndrome?
4. Molecular pathway appears crucial in development of pulmonary fibrosis
5. Evel Knievel Lost to Pulmonary Fibrosis; Disease Claims as Many Lives as Breast Cancer Each Year
6. Free Program Dec. 1 to Help Patients With Debilitating Pulmonary Disorder Alpha-1
7. Nektars Leading PEGylation and Pulmonary Technology Platforms Featured at R&D Day in New York
8. A new method allows for the early diagnosis of pulmonary hypertension
9. Triumph-1 Trial of Viveta in Pulmonary Arterial Hypertension Meets Primary Endpoint
10. Coalition for Pulmonary Fibrosis Fundraising Events Raise $280,000 for IPF
11. Deep Breeze Ltd. Launches Unique Non-Invasive, Radiation-Free Pulmonary Imaging System in the U.S.
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/24/2017)... ... April 24, 2017 , ... Donna Parker, L. Ac. reads ... not found any of them to be very practical. She wanted to write a ... make changes in their health. It prompted her in writing “ A Clear Path ...
(Date:4/24/2017)... ... April 24, 2017 , ... “The Saint with Trin, ... Trin, and Omega Station” is the creation of published author, Chris Jackson. Chris ... where he works in the Dallas Independent School District teaching English. He is heavily ...
(Date:4/24/2017)... , ... April 24, 2017 , ... ... development of next generation neuro-thrombectomy systems for the treatment of Acute Ischemic Stroke ... its ANCD BRAIN device as the product advances towards regulatory and clinical phases. ...
(Date:4/22/2017)... , ... April 22, 2017 , ... Ecommerce sales have ... States estimated to be $394.9 billion. The consequences of rapid innovation and growth ... the limits of technology, it is every business and individual’s job to give something ...
(Date:4/22/2017)... ... 2017 , ... The San Juan Capistrano summer camp team at the Boys and ... for summer camps to provide physical activities for all campers. To read the report, ... , With an increase in specialty camps that focus on what the report terms as ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)... 20, 2017  AbbVie (NYSE: ABBV), a global ... of chronic hepatitis C virus (HCV) infected patients ... and compensated cirrhosis (Child-Pugh A) achieved sustained virologic ... with its investigational, pan-genotypic regimen of glecaprevir/pibrentasvir (G/P). ... following 12 weeks of G/P treatment without ribavirin. ...
(Date:4/20/2017)... DUBLIN , April 20, 2017 ... "Latin America Pharmaceutical Contract Manufacturing Services Market Analysis By Service ... And Segment Forecasts, 2014 - 2025" report to their ... The Latin ... USD 21.0 billion by 2025 Low drug registration ...
(Date:4/19/2017)... 19, 2017  IRIDEX Corporation (Nasdaq: IRIX ... for the first quarter 2017 after the close of ... team will host a corresponding conference call beginning at ... Investors interested in listening to the conference call may ... or (703) 326-3030 for international callers, using conference ID: ...
Breaking Medicine Technology: